

Paradigm activates Hong Kong clinical trial site and commences screening in Phase 3 OA study

Paradigm Biopharmaceuticals Ltd. (ASX: PAR) ("Paradigm" or "the Company") a late-stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to announce the activation of an additional international clinical trial site in Hong Kong for its global Phase 3 clinical study evaluating injectable pentosan polysulfate sodium (iPPS) in patients with knee osteoarthritis.

The newly activated Hong Kong site has now commenced screening patients for participation in the global PARA_OA_012 Phase 3 clinical trial. The site, Hong Kong Centre for Clinical Research, is led by Principal Investigator Dr Edith Lau Ming Chu.

The Company also advises that three clinical trial sites in Moldova are expected to be activated in the coming weeks, further expanding Paradigm's global trial footprint and recruitment capacity.

The activation of the Hong Kong site is timely as the Company rapidly approaches the 50% patient recruitment milestone in the PARA_OA_012 study, required to trigger the interim analysis. The addition of further international sites, including the imminent activation of Moldova, is expected to enhance recruitment momentum and support efficient completion of the remaining enrolment phase.

The Phase 3 study is designed to enrol 466 participants globally, with patients randomised to receive iPPS or placebo. The primary endpoint of the study is the change in weekly average of daily pain at Day 112, with secondary endpoints including improvements in physical function, structural outcomes assessed through imaging, and additional safety and patient-reported outcome measures.

Patient recruitment across Paradigm's international network of clinical trial sites spanning Australia, the United States and now Asia supports the Company's strategy to generate global data for regulatory submission.

The Hong Kong site is supported by NBCD, a contracted research organisation (CRO), working alongside Paradigm's existing CRO, Advanced Clinical, which continues to manage clinical trial operations across Australia and the United States. The Company believes these complementary CRO partnerships strengthen its global recruitment capability as the trial progresses toward full enrolment.

Paradigm also advises that senior management will travel to Hong Kong during the week commencing 13 April 2026 to visit the site and meet with Dr Edith Lau Ming Chu and the clinical team involved in the study.

Paradigm Managing Director, Paul Rennie, said: "As we approach the important 50% recruitment milestone in the PARA_OA_012 study, it is timely that the Hong Kong site has come online to support the next phase of enrolment."

"With additional sites in Moldova expected to be activated shortly, we are continuing to build recruitment momentum and expand our global site network."

"NBCD, which is supporting the Hong Kong and Moldova regions, is working alongside Advanced Clinical, which continues to manage sites across Australia and the United States. Together, these complementary CRO partnerships strengthen our global recruitment network as we work toward completing enrolment in this Phase 3 study."

Paradigm will continue to update the market as the Moldova clinical sites are activated and patient recruitment progresses.

About PARA_OA_012 Phase 3 Trial

PARA_OA_012 is a randomised, double-blind, placebo-controlled, multi-centre study that will evaluate the dose and treatment effect of injectable pentosan polysulfate sodium (iPPS) in participants with knee OA pain. The study's primary objectives focus on pain reduction and functional improvement as measured by validated scales. The trial is expected enrol approximately 466 participants in a 1:1 randomisation design, with an interim analysis planned after the Day 112 pain data from approximately 50% of the total sample size has been collected. This phase 3 trial builds on the positive outcomes of Paradigm's previous phase 2 studies, including the PARA_OA_008 trial, which demonstrated significant clinical benefits in pain reduction and improved joint function for up to 12 months in patients treated with iPPS .

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing iPPS for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3).

Authorised for release by the Paradigm Board of Directors.

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd.

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com



For more information please visit:
<https://investors.paradigmbiopharma.com>

For personal use only